Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial
Archives of Iranian Medicine · 2024
DOI: 10.34172/aim.31839 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Archives of Iranian Medicine, 2024. Verfasst von Elham Jafari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Metabolic Syndrome, Atorvastatin, Blood Glucose, Cardiovascular Diseases. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
While cardiovascular disease (CVD) polypills have demonstrated significant benefits in preventing CVD events by managing CVD risk factors and improving patient adherence, their effects on blood glucose levels, an important risk factor for CVD, remain unknown.
Methods
We analyzed data from the PolyIran-Liver trial, which involved 1,508 participants aged 50 and above. Of these, 787 were randomly assigned to receive a polypill (consisting of aspirin, atorvastatin, hydrochlorothiazide, and valsartan), while 721 received usual care as the control group over a five-year period. The aim was to determine whether there were any significant differences in fasting blood sugar (FBS) levels between the two groups at baseline, middle, and end of the study. The data analysis focused on three subgroups: participants with diabetes, those with metabolic syndrome (MetS) but without diabetes, and participants without diabetes or MetS.
Results
Of the total studied population, with a mean age of 59±6.7 years, 328(22%) were identified with diabetes, 371 (25%) with MetS but without diabetes, and 809 (54%) without diabetes or MetS. We observed a trend of rising FBS levels until month 30, followed by a subsequent decline at month 60. Participants in the polypill group exhibited lower FBS levels than the control group at both time points, with statistically significant differences in all three subgroups at month 30 and in the MetS-without diabetes at month 60 (mean difference: -9.3 mg/dl, 95% CI: 13.9 to -4.6).
Conclusion
The polypill used in this study may have the potential to delay the onset of diabetes in patients with MetS more effectively than in the general population. However, its beneficial effects on the blood sugar levels of diabetic individuals require further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Cardiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
- Research and Development Department, Alborz-Darou Pharmaceutical Co., Ghazvin, Iran.
ORCID-Profile: Elham Jafari, Hossein Poustchi, Masoud Khoshnia, Shahin Merat, Reza Malekzadeh
Zitieren
APA
Jafari, E., Poustchi, H., Mohagheghi, A., Sharafkhah, M., Khoshnia, M., Nateghi, A., Merat, S., & Malekzadeh, R. (2024). Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial. Archives of Iranian Medicine. https://doi.org/10.34172/aim.31839
Vancouver
Jafari E, Poustchi H, Mohagheghi A, Sharafkhah M, Khoshnia M, Nateghi A, et al. Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial. Archives of Iranian Medicine. 2024. doi:10.34172/aim.31839
BibTeX
@article{Jafari2024,
author = {Jafari, Elham and Poustchi, Hossein and Mohagheghi, Abbas and Sharafkhah, Maryam and Khoshnia, Masoud and Nateghi, Alireza and Merat, Shahin and Malekzadeh, Reza},
title = {Preventive Effects of a CVD Polypill on Developing Diabetes Among Patients With Metabolic Syndrome: Results of the PolyIran-Liver Trial},
journal = {Archives of Iranian Medicine},
year = {2024},
doi = {10.34172/aim.31839}
}
EUVIMED